Anticipated revenue decrease of around 6% on a reported basis and an increase of around 2% on a comparable basis (+3% at constant currency)
Fresenius Medical Care supports the recommendation by the United Kingdom’s NICE to facilitate population healthcare management for UK patients with end-stage renal disease.
Healthy organic growth across the board, North American Products business continues strong growth
Fresenius Medical Care Ventures, the venture capital unit of Fresenius Medical Care, announced today that it has invested $2 million in the Series B financing round for Vectorious Medical Technologies.
Fresenius Medical Care today successfully placed notes with an aggregate principal amount of €500 million.
Fresenius Medical Care today announced the closing of the divestiture of Sound Inpatient Physicians Holdings, LLC (Sound) to an investment consortium led by Summit Partners as of June 28, 2018
Revenue in the first quarter 2018 was significantly impacted by a 12% negative impact resulting from foreign currency translation, declining 1% at constant currency to EUR 3,976 million.
Press Release Fresenius Medical Care, the world’s largest provider of dialysis products and services, today announced a leadership change in its EMEA (Europe, Middle East and Africa) region....
